Upstream Processing

Articles

Lonza is expanding its microbial development capabilities at its Visp, Switzerland, site to support clinical and commercial drug development programs.

Lonza Invests in Microbial Development Lab Expansion

A research team at the Keck Graduate Institute will work to adapt its decade-long low-cost vaccine R&D for developing countries into a COVID-19 vaccine.

KGI Team Adapts Vaccine Development Work to Address COVID-19 

Catalent Biologics has launched its new cell line expression technology, GPEx Lightning, which aims to shorten drug substance development timelines by up to three months.

Catalent Biologics Launches New Cell Line Expression Technology

Thermo Fisher Scientific has introduced its new Quick to Clinic solution, which is designed to accelerate biologic drug development from discovery to the IND phase in a shortened period.

Thermo Fisher Scientific’s Clinic Solution Aims to Accelerate Biologic Drug Development

The new VirusExpress lentiviral production platform increases dose yields and reduces process development time for cell and gene therapies.

MilliporeSigma Launches Lentiviral Production Platform for Cell and Gene Therapies

Feliza Mirasol is the science editor for 

An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.

Synthetic Biology Offers a Solution to Cell Therapy Source Material Constraints

The companies will collaborate on the production of a novel anti-SARS-CoV-2 immunoadhesin in iBio’s FastPharming manufacturing system.

iBio and Planet Biotechnology Partner to Develop COVID-19 Therapeutic

In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.

GigaGen Highlights Research Describing New Class of Drugs for Potential COVID-19 Therapy

The company will build an additional commercial-scale, contract manufacturing facility for viral vectors and gene therapies near its existing site in Carlsbad, CA.

MilliporeSigma Adds Viral Vector and Gene Therapy Capacity

The technology enables the rapid production of large numbers of recombinant antibodies at 80-mL scale.

Manufacturing, Expression Systems